One of the most difficult things to predict is when a stock hits a ceiling. There are all sorts of technical and financial measures investors use to judge this yet even with these advanced mathematics stock levels often defy any logical valuations. Given what’s going in the diabetes device space we wonder if we are hitting an inflection point. Consider the following;
Insulet market cap is approaching $10 BILLION
Dexcom up some 31% so far as we write is now approaching the $20 BILLION market cap area
Tandem a company that was nearly dead . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.